Evidence map›Paper›PMID 41262577›Full record

ArticleACS pharmacology & translational science2025

Treatment of Parkinson's Disease with an Anti-Inflammasome NLRP3 Inhibitor Derived from a Natural Product.

Wenqian Li, Jiuliang Zhang, Qiang Chen, Biaobiao Luo, Bo Zhou, Jun Wang, Yang Yang, Yi Liu, Shuixiu Wen, De-Xin Kong and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Wenqian LiInstitute for Medicinal Plants, College of Plant Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.
Jiuliang ZhangCollege of Food Science & Technology, Huazhong Agricultural University, Wuhan 430070, China.ORCID https://orcid.org/0000-0002-1745-846X
Qiang ChenInstitute for Medicinal Plants, College of Plant Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.
Biaobiao LuoCollege of pharmacy, Xinxiang Medical University, Xinxiang, Henan 453003, China.
Bo ZhouInstitute for Medicinal Plants, College of Plant Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.
Jun WangInstitute for Medicinal Plants, College of Plant Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.
Yang YangInstitute for Medicinal Plants, College of Plant Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.
Yi LiuCollege of Informatics, Huazhong Agricultural University, Wuhan 430070, China.
Shuixiu WenCollege of Informatics, Huazhong Agricultural University, Wuhan 430070, China.
De-Xin KongCollege of Informatics, Huazhong Agricultural University, Wuhan 430070, China.
Jian ChenHubei Cancer Hospital, Tongji Medical College, Colorectal cancer clinical research center of Hubei Province, Colorectal cancer clinical research center of Wuhan, Huazhong University of Science and Technology, Wuhan 430070, China.
Shaozhong WeiHubei Cancer Hospital, Tongji Medical College, Colorectal cancer clinical research center of Hubei Province, Colorectal cancer clinical research center of Wuhan, Huazhong University of Science and Technology, Wuhan 430070, China.
Pierre DuezUnit of Therapeutic Chemistry and Pharmacognosy, Faculty of Medicine and Pharmacy, Research Institute for Health Sciences and Technology, University of Mons-UMONS, Mons 7000, Belgium.
Avez SharipovScientific Laboratory of Innovative Pharmaceutical Compounds, Tashkent Pharmaceutical Institute, Oybek Street 45, Tashkent 100015, Uzbekistan.
Yan LiInstitute for Medicinal Plants, College of Plant Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.
Xuebo HuInstitute for Medicinal Plants, College of Plant Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.ORCID https://orcid.org/0000-0002-1904-9870

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD), the second most prevalent neurodegenerative disorder afflicting human health, is primarily characterized by the degeneration of dopaminergic neurons in the midbrain, leading to movement disorders as the main clinical manifestation. Extensive research has demonstrated that the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome and its accompanying neuroinflammation play a pivotal role in the progression of PD. ST-4, namely 15-oxosteviol, an analogue of the diterpene oridonin, exhibits potent and specific inhibition of NLRP3 in

Indexed as

15-oxosteviolFBDDnatural productsoridoninST-4steviolstevioside

Identifiers

PMID41262577
PMCPMC12624427

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.